Table 2.
Ovarian and primary peritoneal cancers grouped by primary site and screening status
| Total* | Screen positives |
Cancers not detected by screening |
|||||
|---|---|---|---|---|---|---|---|
| Screen negatives <1 year from last test of screening episode† | Screen negatives >1 year after last test of screening episode | After screening phase‡ | Never attended screening | ||||
| MMS (50 624 women, 548 533 women-years) | |||||||
| Primary ovarian cancer | 338 (100%) | 199 (59%) | 38 (11%) | 41 (12%) | 57 (17%) | 3 (1%) | |
| Primary non-epithelial neoplasm of ovary (ICD C56) | 11 (100%) | 7 (64%) | 2 (18%) | 2 (18%) | 0 | 0 | |
| Primary borderline epithelial neoplasm of ovary (ICD C56) | 44 (100%) | 24 (55%) | 10 (23%) | 5 (11%) | 5 (11%) | 0 | |
| Primary invasive epithelial neoplasm of ovary (ICD C56) | 244 (100%) | 147 (60%) | 21 (9%) | 29 (12%) | 44 (18%) | 3 (1%) | |
| Primary invasive epithelial neoplasm of fallopian tube (ICD C57.0) | 19 (100%) | 13 (68%) | 2 (11%) | 0 | 4 (21%) | 0 | |
| Undesignated (unable to delineate if primary site ovary or fallopian tube or peritoneum) | 20 (100%) | 8 (40%) | 3 (15%) | 5 (25%) | 4 (20%) | 0 | |
| Primary peritoneal cancer | 16 (100%) | 13 (81%) | 3 (19%) | 0 | 0 | 0 | |
| USS (50 623 women, 548 825 women-years) | |||||||
| Primary ovarian cancer | 314 (100%) | 161 (51%) | 60 (19%) | 46 (15%) | 34 (11%) | 13 (4%) | |
| Primary non-epithelial neoplasm of ovary (ICD C56) | 12 (100%) | 11 (92%) | 0 | 1 (8%) | 0 | 0 | |
| Primary borderline epithelial neoplasm of ovary (ICD C56) | 53 (100%) | 48 (91%) | 2 (4%) | 1 (2%) | 0 | 2 (4%) | |
| Primary invasive epithelial neoplasm of ovary (ICD C56) | 220 (100%) | 93 (42%) | 48 (22%) | 37 (17%) | 31 (14%) | 11 (5%) | |
| Primary invasive epithelial neoplasm of fallopian tube (ICD C57.0) | 13 (100%) | 4 (31%) | 3 (23%) | 3 (23%) | 3 (23%) | 0 | |
| Undesignated (unable to delineate if primary site ovary or fallopian tube or peritoneum) | 16 (100%) | 5 (31%) | 7 (44%) | 4 (25%) | 0 | 0 | |
| Primary peritoneal cancer | 10 (100%) | 3 (30%) | 3 (30%) | 4 (40%) | 0 | 0 | |
| No screening (101 299 women, 1 097 089 women-years) | |||||||
| Primary ovarian cancer | 630 (100%) | .. | 501 (80%) | .. | 129 (20%) | .. | |
| Primary non-epithelial neoplasm of ovary (ICD C56) | 8 (100%) | .. | 7 (88%) | .. | 1 (13%) | .. | |
| Primary borderline epithelial neoplasm of ovary (ICD C56) | 62 (100%) | .. | 50 (81%) | .. | 12 (19%) | .. | |
| Primary invasive epithelial neoplasm of ovary (ICD C56) | 493 (100%) | .. | 392 (80%) | .. | 101 (20%) | .. | |
| Primary invasive epithelial neoplasm of fallopian tube (ICD C57.0) | 28 (100%) | .. | 21 (75%) | .. | 7 (25%) | .. | |
| Undesignated (unable to delineate if primary site ovary or fallopian tube or peritoneum) | 38 (100%) | .. | 30 (79%) | .. | 8 (21%) | .. | |
| Primary ovarian neoplasm (histology not available) | 1 (100%) | .. | 1 (100%) | .. | 0 | .. | |
| Primary peritoneal cancer | 15 (100%) | .. | 15 (100%) | .. | 0 | .. | |
Data are n (%). MMS=multimodal screening. ICD=International Classification of Diseases. USS=ultrasound screening.
Includes in the MMS group, three screen-positive neoplasms of uncertain malignancy that have been recoded by outcomes review as non-epithelial ovarian cancer and one screen-positive borderline that has been recoded as invasive after the published incidence analysis; in the USS group, it includes five screen-positive neoplasms of uncertain malignancy that have been recoded by outcomes review as non-epithelial ovarian cancer and two additional screen-negative invasive epithelial ovarian cancers that were identified after the published prevalence analysis.
For the no screening group, this category applies during the screening phase.
Refers to more than 1 year after last potential screen in 2011 based on the anniversary of an individual's randomisation date.